Drug Patent Watch
OCTOBER 9, 2024
The pharmaceutical industry plays a crucial role in global healthcare, providing essential medications that improve and save lives. Within this industry, generic pharmaceuticals are particularly important due to their affordability and accessibility.
Bio Pharma Dive
OCTOBER 9, 2024
Many pharma companies are now using de-identified lab data to identify potential patients and their physicians in time to impact the patient’s treatment plan. In this Q&A, learn how lab data can be used to increase patient access.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 9, 2024
City Therapeutics has announced its launch accompanied by a $135m Series A financing to lead advancements in RNAi-based medicine.
Bio Pharma Dive
OCTOBER 9, 2024
Thomas Fuchs will lead artificial intelligence initiatives across Lilly, including in drug discovery, clinical trials and manufacturing.
Rethinking Clinical Trials
OCTOBER 9, 2024
Dr. Shawn Aaron In this Friday’s PCT Grand Rounds, Shawn Aaron of the University of Ottawa will present “Early Diagnosis and Treatment of Asthma and COPD.” The Grand Rounds session will be held on Friday, October 11, 2024, at 1:00 pm eastern. Aaron is a professor of medicine at the University of Ottawa and the director of the Canadian Respiratory Research Network.
Bio Pharma Dive
OCTOBER 9, 2024
The company, which is building a database of biological interactions found in nature, revealed $60 million in funding and a collaboration with David Liu’s lab.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
OCTOBER 9, 2024
The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.
Pharmaceutical Technology
OCTOBER 9, 2024
The company employs machine learning to uncover disease mechanisms at the mRNA level and to identify therapeutic candidates.
Bio Pharma Dive
OCTOBER 9, 2024
AlphaFold’s developers were awarded science’s top prize. Elsewhere, J&J is shuttering an intriguing cancer study and Alnylam is asking for approval of a drug that could rival a Pfizer blockbuster.
Pharmaceutical Technology
OCTOBER 9, 2024
The US FDA has declined to approve Zealand Pharma's dasiglucagon for hypoglycaemia in infants with congenital hyperinsulinism (CHI).
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Bio Pharma Dive
OCTOBER 9, 2024
The Series B round will fund a Phase 1/2 trial of the company’s experimental treatment for IgA nephropathy.
Pharmaceutical Technology
OCTOBER 9, 2024
The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s fibroblast platform.
Rethinking Clinical Trials
OCTOBER 9, 2024
Speakers Tyler Winkelman, MD, MSc Division Director, General Internal Medicine Hennepin Healthcare Co-Director, Health, Homelessness, and Criminal Justice Lab HHRI David Johnson, MPH Health Informatics and Epidemiology Program Manager Hennepin County Slides Keywords Electronic Health Record; Data Sharing; Public Health; Health Systems; Partnerships Key Points Collaboration across public health and health care is essential to developing actionable data
Pharmaceutical Technology
OCTOBER 9, 2024
Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to clinic.
Fierce Pharma
OCTOBER 9, 2024
GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by us | GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
Pharmaceutical Technology
OCTOBER 9, 2024
Emergent said it is separately working on increasing the availability of its overdose reverser on site for businesses.
Fierce Pharma
OCTOBER 9, 2024
A trial of Biogen’s spinal muscular atrophy therapy Spinraza suggests that a higher dose provides benefits to a broad range of patients.
Pharmaceutical Technology
OCTOBER 9, 2024
As a major report highlights the challenges of a struggling NHS, the call for preventative care is growing in the UK.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
OCTOBER 9, 2024
With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the company’s executives will reportedly hear out activist investor Starboard Valu | Activist investor Starboard Value recently picked up a $1 billion stake in the drugmaker and will now pitch a strategy shift to top executives, the Financial Times reported.
pharmaphorum
OCTOBER 9, 2024
Sage Therapeutics stops development of dalzanemdor in Alzheimer's, a few months after pulling the plug on the drug in Parkinson's
Fierce Pharma
OCTOBER 9, 2024
Amid a transformation effort under CEO Christophe Bourdon, Danish dermatology expert Leo Pharma is embarking on another round of layoffs and relocations. | Leo is closing and relocating up to 250 roles as part of the “next step” in the dermatology company’s evolving strategy, a company spokesperson told Fierce Pharma. Most jobs affected by the move are based in Leo’s home country of Denmark and span “all business areas.
Drug Channels
OCTOBER 9, 2024
As regular readers of Drug Channels know, U.S. distribution and dispensing channels for prescription drugs are undergoing significant evolution and consolidation as the changing economics of pharmaceuticals challenge conventional business models. During this period of volatility, the core business model of the Big Three public pharmaceutical distribution companies—Cardinal Health, Cencora, and McKesson—remains intact.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
OCTOBER 9, 2024
Ex-Pfizer CEO and finance chief withdraw support for Starboard Value campaign seeking a change in strategy at the pharma group.
Fierce Pharma
OCTOBER 9, 2024
After third-party manufacturing issues led to a December rejection of Zealand Pharma’s pediatric congenital hyperinsulinism (CHI) candidate, the Danish pharma’s latest snub seems to come down to ti | Zealand’s glucagon receptor agonist dasiglucagon has been rebuffed by the FDA once again, scrambling the company's plan to launch the hypoglycemia treatment in kids with congenital hyperinsulinism.
pharmaphorum
OCTOBER 9, 2024
Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market.For the second time in less than a year, the FDA has issued a complete response letter to the company citing the need for data on a third-party manufacturing site that had failed an earlier inspection by the agency.
Fierce Pharma
OCTOBER 9, 2024
A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected for a variety of common eye diseases, Clearside Biomedical is making sign | Clearside’s CLS-AX (axitinib injectable suspension) has aced a phase 2b trial, achieving its primary and secondary outcomes for patients with neovascular age-related macular degeneration (wet AMD).
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
OCTOBER 9, 2024
Lilly names Thomas Fuchs as its first chief AI officer Phil.
Pharma Times
OCTOBER 9, 2024
New investment to advance gene therapies for kidney diseases
pharmaphorum
OCTOBER 9, 2024
Explore how GenAI is disrupting the healthcare industry with digital innovation and the Direct-To-Patient model. Learn how this innovative approach is transforming patient care and access to medical services.
Pharma Times
OCTOBER 9, 2024
New vaccine aims to protect older adults from severe flu complications
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
87 
Let's personalize your content